Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.72 |
| ▸ | HTR3B | O95264 | 1/20 | 0.72 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.72 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.72 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.72 |
| ▸ | HTR3A | P46098 | 1/20 | 0.72 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.72 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.72 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.72 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7404970 | 0.94 | CYP3A4 (0.65) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Maleic Acid SCHEMBL7404967 | 0.94 | CYP3A4 (0.65) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL21974469 | 0.88 | CYP3A4 (0.78) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL9834638 | 0.87 | CYP3A4 (0.76) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Hydrochloric Acid SCHEMBL7407971 | 0.87 | CYP3A4 (0.75) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL9837125 | 0.86 | CYP3A4 (0.74) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL9835755 | 0.86 | CYP3A4 (0.74) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL9837022 | 0.85 | CYP3A4 (0.72) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL7408093 | 0.85 | CYP3A4 (0.72) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL1560211 | 0.84 | CYP3A4 (1.00) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4695578-A | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances | GLAXO GROUP LIMITED (GB) | 1987-09-22 | — | — | US | claimed |
| EP-0226266-A2 | Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments | GLAXO GROUP LIMITED (GB) | 1987-06-24 | — | — | EP | claimed |
| EP-0221629-A1 | Process for the preparation of 3-imidazolylmethyltetrahydrocarbazolones | GLAXO GROUP LIMITED (GB) | 1987-05-13 | — | — | EP | claimed |
| EP-0219929-A1 | Process for the preparation of 3-imidazolylmethyltetrahydrocarbazolones | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | claimed |
| US-8580730-B2 | Methods of treating lesional vestibular disorders by administering serotonin 5-HT3 receptor antagonists | (INSERM) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2253316-B1 | Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits | INST NAT SANTE RECH MED (FR) | 2013-08-14 | — | — | EP | disclosed |
| EP-2432467-A1 | SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-03-28 | — | — | EP | disclosed |
| US-20120064094-A1 | Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133663-A1 | SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-11-25 | — | — | WO | disclosed |
| EP-2253316-A1 | serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of vestibular deficits | INSERM (Institut National de la Santé et de la Recherche Medicale) (FR) | 2010-11-24 | — | — | EP | disclosed |
| US-6569883-B1 | Such as R-1,2,3,9-tetrahydro-3-((2-methyl-1H-imidazol-1-yl) methyl)-9- methyl-4H-carbazol-4-one hydrochloride dihydrate adapted for rectal administration for relief of nausea and vomiting and/or the promotion of gastric emptying | GLAXO GROUP LIMITED (GB) | 2003-05-27 | — | — | US | disclosed |
| US-5922749-A | ADMINISTERING TO A HUMAN OR ANIMAL THE DRUG ONDANSETRON (R-1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)M ETHYL)-4H-CAR BAZOL-4-ONE) OR A PHYSIOLOGICALLY ACCEPTABLE SALT OR SOLVATE | GLAXO GROUP LIMITED (GB) | 1999-07-13 | — | — | US | disclosed |
| US-4957609-A | CYCLIZATION | GLAXO GROUP LIMITED (GB) | 1990-09-18 | — | — | US | disclosed |
| US-4929632-A | EMETIC AGENTS, ANTIEMETIC AGENTS, CARBAZOL-4-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1990-05-29 | — | — | US | disclosed |
| US-4753789-A | Method for treating nausea and vomiting | GLAXO GROUP LIMITED (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4739072-A | CYCLIZATION OF HYDRAZINE COMPOUND | SANOFI (FR) | 1988-04-19 | — | — | US | disclosed |
| US-4695578-A | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances | GLAXO GROUP LIMITED (GB) | 1987-09-22 | — | — | US | disclosed |
| EP-0226266-A2 | Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments | GLAXO GROUP LIMITED (GB) | 1987-06-24 | — | — | EP | disclosed |
| EP-0221629-A1 | Process for the preparation of 3-imidazolylmethyltetrahydrocarbazolones | GLAXO GROUP LIMITED (GB) | 1987-05-13 | — | — | EP | disclosed |
| EP-0219929-A1 | Process for the preparation of 3-imidazolylmethyltetrahydrocarbazolones | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064094-A1 | Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders | HTR3A, HTR3B, HTR3E | CYP3A4 4564/4885KCNH2 1651/4885CYP1A2 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.